China smartphone shipments slumped in June on inventory overhang: Jefferies
Christopher Anzalone, the CEO of Arrowhead Pharmaceuticals (NASDAQ:ARWR), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the SEC, Anzalone sold a total of 141,122 shares over several transactions from April 9 to April 11, 2025, amounting to approximately $1.53 million. The shares were sold at prices ranging from $9.93 to $11.76 per share. The stock has shown recent momentum with a 10.39% gain over the past week, though it remains down 37% year-to-date.
The transactions were carried out to cover taxes associated with the vesting of restricted stock awards, as noted in the filing. Following these sales, Anzalone retains ownership of 3,921,255 shares of Arrowhead Pharmaceuticals. The sales were executed in multiple transactions, with the largest single sale being 50,800 shares on April 11 at $11.49 each. According to InvestingPro, the company maintains strong liquidity with a current ratio of 6.09, indicating its ability to meet short-term obligations.
Investors often closely monitor insider transactions like these for insights into executive sentiment and company performance. Arrowhead Pharmaceuticals, headquartered in Pasadena, California, is involved in developing pharmaceutical preparations. InvestingPro analysis suggests the stock is currently overvalued, with analysts anticipating sales growth in the current year. The company is scheduled to report its next earnings on May 8, 2025. Get access to 8 more exclusive ProTips and comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, Arrowhead Pharmaceuticals has reported positive results from a Phase 1/2 clinical trial of its investigational drug ARO-C3, aimed at treating IgA nephropathy, a kidney disease. The study demonstrated significant reductions in key markers of disease activity and proteinuria, with no serious adverse events reported. Additionally, Arrowhead is advancing its RNA interference-based therapies for obesity, ARO-INHBE and ARO-ALK7, into clinical trials, showing promising preclinical results in reducing body fat while preserving lean muscle mass. In corporate governance developments, Arrowhead’s shareholders approved all proposed items at the 2025 Annual Meeting, including the election of directors and advisory votes on executive compensation. The company also ratified KPMG LLP as its independent auditor for the fiscal year ending September 30, 2025. Analyst firms have weighed in on Arrowhead’s prospects, with H.C. Wainwright maintaining a Buy rating and a $80 price target, citing confidence in the ARO-C3 program. Meanwhile, Goldman Sachs reiterated a Neutral rating with a $26 target, highlighting the need for longer-term data on ARO-C3. Arrowhead is also preparing for the launch of plozasiran for familial chylomicronemia syndrome, with a PDUFA date set for November 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.